Xilio Therapeutics Inc [XLO] stock is trading at $0.81, up 7.60%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The XLO shares have gain 4.36% over the last week, with a monthly amount glided 6.83%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xilio Therapeutics Inc [NASDAQ: XLO] stock has seen the most recent analyst activity on August 06, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $2. Previously, Chardan Capital Markets started tracking the stock with Buy rating on December 21, 2022, and set its price target to $7. On January 10, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $36 on the stock. Raymond James started tracking the stock assigning a Outperform rating and suggested a price target of $31 on November 16, 2021. Morgan Stanley initiated its recommendation with a Overweight and recommended $32 as its price target on November 16, 2021. Guggenheim started tracking with a Buy rating for this stock on November 16, 2021, and assigned it a price target of $40. In a note dated November 16, 2021, Cowen initiated an Outperform rating.
Xilio Therapeutics Inc [XLO] stock has fluctuated between $0.62 and $1.70 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Xilio Therapeutics Inc [NASDAQ: XLO] shares were valued at $0.81 at the most recent close of the market. An investor can expect a potential return of 764.2% based on the average XLO price forecast.
Analyzing the XLO fundamentals
Xilio Therapeutics Inc [NASDAQ:XLO] reported sales of 31.80M for the trailing twelve months, which represents a growth of 742.51%. Gross Profit Margin for this corporation currently stands at 0.4% with Operating Profit Margin at -1.38%, Pretax Profit Margin comes in at -1.33%, and Net Profit Margin reading is -1.33%. To continue investigating profitability, this company’s Return on Assets is posted at -0.32, Equity is -6.19 and Total Capital is -0.57. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.9.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7641 points at the first support level, and at 0.7213 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8284, and for the 2nd resistance point, it is at 0.8499.
Ratios To Look Out For
For context, Xilio Therapeutics Inc’s Current Ratio is 2.20. Further, the Quick Ratio stands at 2.20, while the Cash Ratio is 1.84. Considering the valuation of this stock, the price to sales ratio is 1.33.
Transactions by insiders
Recent insider trading involved Shannon James Samuel, Director, that happened on Jun 16 ’25 when 45000.0 shares were purchased. Director, Shannon James Samuel completed a deal on Jun 17 ’25 to buy 25000.0 shares. Meanwhile, PRESIDENT AND CEO Russo Rene bought 36289.0 shares on Jun 16 ’25.
